• de MacedoJuliana Ribeiro Fonseca FrancoJRFFMs Franco de Macedo and Drs Reychler and Poncin are affiliated with Institute de Recherche Expérimentale et Clinique, Pôle de Pneumologie, ORL and Dermatologie, Université Catholique de Louvain, 1200 Brussels, Be, Elinaldo da Conceiçãodos Dos Santos, Gregory Reychler, and William Poncin.
• Ms Franco de Macedo and Drs Reychler and Poncin are affiliated with Institute de Recherche Expérimentale et Clinique, Pôle de Pneumologie, ORL and Dermatologie, Université Catholique de Louvain, 1200 Brussels, Belgium; Service de Pneumologie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; and Secteur de Kinésithérapie et Ergothérapie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium. Dr Conceição dos Santos is affiliated with Department of Biological and Health Sciences. Universidade Federal do Amapá, Macapá, Brazil.
• Respir Care. 2024 Feb 28; 69 (3): 366375366-375.

BackgroundLung hyperinflation is a typical clinical feature of patients with COPD. Given the association between breathing at elevated lung volumes and the manifestation of severe debilitating symptoms, therapeutic interventions such as positive expiratory pressure (PEP) therapy and its variations (temporary, oscillatory) have been devised to mitigate lung hyperinflation. However, the efficacy of these interventions remains to be conclusively demonstrated.MethodsA systematic review with meta-analysis of randomized trials was conducted following the PRISMA guidelines. Seven databases were screened with no date or language restriction. Two authors independently applied eligibility criteria and assessed the risk of bias of included studies using the Cochrane risk-of-bias tool. Outcomes were lung hyperinflation measures detected through changes in inspiratory capacity (IC), functional residual capacity (FRC), total lung capacity (TLC), and residual volume (RV), as well as FEV1, FVC, dyspnea, and physical capacity. Pooled standardized mean differences (SMDs) or mean differences (MDs) and 95% CI were calculated using a random-effects model.ResultsSeven trials, all with a high risk of bias, were included. Compared to control group, RV significantly decreased (4 studies, n = 231; SMD -0.42 [95% CI -0.77 to -0.08], P = .02), dyspnea improved (n = 321, SMD -1.17 [95% CI -1.68 to -0.66], P < .001), and physical capacity increased (5 studies, n = 311; MD 30.1 [95% CI 19.2-41.0] m, P < .001) with PEP therapy. There was no significant difference between PEP therapy and the control group in TLC, FVC, or FEV1. Only one study reported changes in inspiratory capacity as well as FRC.ConclusionsIn patients with COPD, the effect of PEP therapy on lung hyperinflation is unclear owing to the non-consistent change in lung hyperinflation outcomes, insufficient data, and lack of high-quality trials. Dyspnea and physical capacity might improve with PEP therapy.Copyright © 2024 by Daedalus Enterprises.

31 keywords...

hide…